Intrinsiqq
Exelixis Inc. logo

Exelixis Inc. Quality Score

EXEL

⊜ Compare
Quality97

Strong across all measured dimensions. No single area is pulling the score down meaningfully.

Broad-market heuristics · Not a buy/sell signal

Valuation and growth

Earnings Multiple
80/100
21.7x

20–25x range, moderate premium

Cash Flow Multiple
90/100
15.3x

Under 20x cash flow, well covered

Revenue Growth
100/100
11.6%

Above 10% CAGR, strong compounder

Cash Flow Growth
100/100
36.5%

Above 10% CAGR, strong compounder

Business Quality & Capital Allocation

Share Dilution
100/100
-21.2%

Shrinking >2%, active buybacks

Margin Trend
100/100
+27.7pp

Expanded 3+pp, strong improvement

Capital Structure
100/100
-$730M

Net cash position, no leverage concern

2022
$1.31B
$208M
2023
$995M
$216M
2025
$1.11B
$216M
2026
$1.06B
$201M
TTM
$892M
$162M
CashDebt
Return on Capital
100/100
38.8%

Above 20%, exceptional capital efficiency

Customize WeightsPremiumUpgrade

Exelixis (EXEL) quality: score, margins and returns

Exelixis (EXEL) scores 97/100 on Intrinsiqq's quality score (a high-quality business), a weighted blend of 8 metrics each scored 0 to 100, on 40.2% operating margins and 38.8% ROIC. Every metric is computed from SEC filings; this is analysis, not investment advice.

Frequently asked

Is Exelixis (EXEL) a high-quality business?+

Exelixis scores 97 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which rates it a high-quality business on these measures. Recent figures include a 40.2% operating margin and a 38.8% return on invested capital. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.

What does Exelixis's quality score measure?+

Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from EXEL's SEC filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where Exelixis scores well and where it falls behind.

What is Exelixis's return on invested capital (ROIC)?+

Exelixis earns about 38.8% on its invested capital, which is exceptional. ROIC measures how much profit a company generates per dollar put to work; sustained ROIC above its cost of capital is one of the clearest signs of a real competitive moat. Compare it to EXEL's margins and growth on this scorecard to judge durability.

How profitable is Exelixis?+

Exelixis runs an operating margin of about 40.2% and a net margin of about 35.5%. Revenue has grown at roughly 18.6% a year recently. High, stable margins usually point to pricing power and operating discipline. Margins are most telling next to growth and returns on capital, all of which feed this quality score. This is analysis from SEC filings, not investment advice.

How the market compares: US profitability statistics

SourceQuality score computed from the 10-Q filed 19 Oct 2026, covering the period ending 2 Oct 2026, as reported to the SEC. Data last refreshed 30 Oct 2026. How this is calculated.

Fiscal year ends Jan. Sector medians are approximate S&P 500 benchmarks and update periodically. Checks use broad-market heuristics, so sector norms may differ, and the valuation checks are more cyclical than the quality checks.

Peers

Biological Products, (No Diagnostic Substances) · Pick stocks to compare with EXEL

CompareIntrinsic value
INCYIncyte Corporation
$122.83+4.46%43
JAZZJazz Pharmaceuticals plc
$234.66+2.14%58
HALOHalozyme Therapeutics Inc.
$130.34+1.34%66
BMRNBiomarin Pharmaceutical Inc.
$57.13+2.64%47
NBIXNeurocrine Biosciences Inc.
$167.21+1.43%85

Held by ETFs

EXEL is in 213 US ETFs. The largest of them, with EXEL's weight in each:

Spot a number that looks wrong? Check it in EXEL's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing EXEL

Create a free account and get 14 days of Premium: every stock and every tool.

  • Unlimited stocks
  • Stock screener
  • Portfolio tracker
  • Editable DCF
  • Compare side by side
  • Unlimited alerts

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.